A Phase 1 interventional study of Lenvatinib 10 mg in Healthy Volunteers, sponsored by Eisai Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-14.
Sponsored by Eisai Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This will be a randomized, single dose, open-label, three-treatment period crossover study in healthy participants to determine whether 2 test lots of 10-mg capsules that vary by the level of lenvatinib Type-C crystal are bioequivalent to a reference lot of 10-mg capsules.
The study will consist of 2 phases: Prerandomization and Randomization. The Prerandomization Phase will have 2 periods: Screening and Baseline. The Randomization Phase will consist of three 6-day long Treatment Periods with each Treatment Period separated by a 1-day long Baseline. Sixty participants will be evenly randomized to 1 of 6 possible treatment sequences (A, B, C, D, E, or F). The 3 treatments vary by the level of crystalline polymorph Type-C present in the drug product batch used in each arm, respectively: Treatment 1 - low Type-C crystal level less than 12%; Treatment 2 - reference Type-C crystal level 12% to 26%; and Treatment 3 - high Type-C crystal level greater than 26%.
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive one dose of Treatment 1 followed by one dose of Treatment 2, then one dose of Treatment 3
Drug: Lenvatinib 10 mg
Participants will receive one dose of Treatment 2, followed by one dose of Treatment 3, then one dose of Treatment 1
Drug: Lenvatinib 10 mg
Participants will receive one dose of Treatment 3, followed by one dose of Treatment 1, then one dose of Treatment 2
Drug: Lenvatinib 10 mg
Participants will receive one dose of Treatment 3, followed by one dose of Treatment 2, then one dose of Treatment 1
Drug: Lenvatinib 10 mg
Participants will receive one dose of Treatment 1, followed by one dose of Treatment 3, then one dose of Treatment 2
Drug: Lenvatinib 10 mg
Participants will receive one dose of Treatment 2, followed by one dose of Treatment 1, then one dose of Treatment 3
Drug: Lenvatinib 10 mg
Treatment 1: low Type-C crystal level \<12% Treatment 2: reference\* Type-C crystal level 12% to 26% Treatment 3: high Type-C crystal level \>26%
Also known as: E7080;Lenvima
Area Under the Plasma Concentration-Time Curve From Zero Time (Predose) to Time of Last Quantifiable Concentration (AUC(0-t))
Blood samples (6 mL each) were collected at the following time points for each Period: 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. The window for 0 to 12 hours was +/-2 minutes, for 24 hours was +/-5 minutes and for \>24 hours was equal to +/-15 to 60 minutes. Plasma concentrations of lenvatinib were quantified by chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) methodology using a previously validated assay. The lower limit of quantitation (LLOQ) for the assay was 0.25 ng/mL. AUC(0-t) was calculated by the linear-up log-down trapezoidal method. No concentration estimates were provided for missing sample values. Any sample with a missing value was treated as if the sample had not been scheduled for collection.
Time frame: Periods 1, 2, and 3; 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose
Area Under the Concentration-Time Curve From Zero Time (Predose) Extrapolated to Infinite Time (AUC(0-inf))
Blood samples (6 mL each) were collected at the following time points for each Period: 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. The window for 0 to 12 hours was +/-2 minutes, for 24 hours was +/-5 minutes and for \>24 hours was equal to +/-15 to 60 minutes. Plasma concentrations of lenvatinib were quantified by LC-MS/MS methodology using a previously validated assay. The LLOQ for the assay was 0.25 ng/mL. AUC(0-t) was calculated by the linear-up log-down trapezoidal method. AUC(0-inf) was calculate as follows; (AUC(0-inf)) = (AUC(0-t)) + (Ct/Kel), where Ct is the last measurable drug concentration and Kel is the elimination rate constant. The apparent first-order Kel was estimated, when possible, from the slope of the regression line for the terminal ln-linear concentration-time values.
Time frame: Periods 1, 2, and 3; 0 (Predose), 2, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose.
Area Under the Concentration-Time Curve From Zero Time (Predose) to 24 Hours (AUC(0-24))
Blood samples (6 mL each) were collected at the following time points for each Period: 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. The window for 0 to 12 hours was +/-2 minutes, for 24 hours was +/-5 minutes and for \>24 hours was equal to +/-15 to 60 minutes. Plasma concentrations of lenvatinib were quantified by LC-MS/MS methodology using a previously validated assay. The LLOQ for the assay was 0.25 ng/mL.
Time frame: Periods 1, 2, and 3; 0 (Predose), 1, 2, 3, 4, 8, 12, and 24 hours postdose
Area Under the Concentration-Time Curve From Zero Time (Predose) to 72 Hours (AUC(0-72))
Blood samples (6 mL each) were collected at the following time points for each Period: 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. The window for 0 to 12 hours was +/-2 minutes, for 24 hours was +/-5 minutes and for \>24 hours was equal to +/-15 to 60 minutes. Plasma concentrations of lenvatinib were quantified by LC-MS/MS methodology using a previously validated assay. The LLOQ for the assay was 0.25 ng/mL.
Time frame: Periods 1, 2, and 3; 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, and 72 hours postdose
Maximum Observed Concentration (Cmax) of Lenvatinib in Plasma
Blood samples (6 mL each) were collected at the following time points for each Period: 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. The window for 0 to 12 hours was +/-2 minutes, for 24 hours was +/-5 minutes and for \>24 hours was equal to +/-15 to 60 minutes. Plasma concentrations of lenvatinib were quantified by LC-MS/MS methodology using a previously validated assay. The LLOQ for the assay was 0.25 ng/mL.
Time frame: Periods 1, 2, and 3; 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose
Time to Cmax (Tmax) for Lenvatinib
Blood samples (6 mL each) were collected at the following time points for each Period: 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. The window for 0 to 12 hours was +/-2 minutes, for 24 hours was +/-5 minutes and for \>24 hours was equal to +/-15 to 60 minutes. Plasma concentrations of lenvatinib were quantified by LC-MS/MS methodology using a previously validated assay. The LLOQ for the assay was 0.25 ng/mL.
Time frame: Periods 1, 2, and 3; 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose
Terminal Elimination Phase Half-life (t1/2)
Blood samples (6 mL each) were collected at the following time points for each Period: 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. The window for 0 to 12 hours was +/-2 minutes, for 24 hours was +/-5 minutes and for \>24 hours was equal to +/-15 to 60 minutes. Plasma concentrations of lenvatinib were quantified by LC-MS/MS methodology using a previously validated assay. The LLOQ for the assay was 0.25 ng/mL.
Time frame: Periods 1, 2, and 3; 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose
Number of Participants With Non-Serious Treatment-Emergent Adverse Events (TEAEs) and Serious Treatment-Emergent Adverse Events as a Measure of Safety and Tolerability of Lenvatinib
Safety assessments consisted of monitoring and recording all adverse events (AEs) (serious and non-serious); regular monitoring of hematology, blood chemistry and urine values; periodic measurement of vital signs and electrocardiograms, performance of physical examinations. A TEAE was defined as an AE that emerges during treatment, having been absent at pretreatment (Baseline), or reemerges during treatment, having been present at pretreatment but stopped before treatment, or worsens in severity during treatment relative to the pretreatment state, when the AE is continuous. TEAEs considered by the investigator to be possibly or probably related to study drug, or TEAEs with missing causality, were included.
Time frame: From date of first dose up to 30 days after the last dose of study treatment, up to approximately 2 months
| Milestone | Sequence A | Sequence B | Sequence C | Sequence D | Sequence E | Sequence F |
|---|---|---|---|---|---|---|
| Started | 10 | 10 | 10 | 10 | 10 | 10 |
| Completed | 9 | 10 | 10 | 10 | 10 | 10 |
| Not completed | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence A | Sequence B | Sequence C | Sequence D | Sequence E | Sequence F |
|---|---|---|---|---|---|---|
| Started | 9 | 10 | 10 | 10 | 10 | 10 |
| Completed | 9 | 10 | 10 | 10 | 10 | 10 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence A | Sequence B | Sequence C | Sequence D | Sequence E | Sequence F |
|---|---|---|---|---|---|---|
| Started | 9 | 10 | 10 | 10 | 10 | 10 |
| Completed | 9 | 9 | 10 | 10 | 10 | 10 |
| Not completed | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Consumption of restricted item | 0 | 1 | 0 | 0 | 0 | 0 |
Blood samples (6 mL each) were collected at the following time points for each Period: 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. The window for 0 to 12 hours was +/-2 minutes, for 24 hours was +/-5 minutes and for \>24 hours was equal to +/-15 to 60 minutes. Plasma concentrations of lenvatinib were quantified by chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) methodology using a previously validated assay. The lower limit of quantitation (LLOQ) for the assay was 0.25 ng/mL. AUC(0-t) was calculated by the linear-up log-down trapezoidal method. No concentration estimates were provided for missing sample values. Any sample with a missing value was treated as if the sample had not been scheduled for collection.
| ng·hr/mL | Treatment 1: Low Crystal Form | Treatment 2: Reference Crystal Form | Treatment 3: High Crystal Form |
|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Zero Time (Predose) to Time of Last Quantifiable Concentration (AUC(0-t)) | 1010 ± 40.4 | 1010 ± 36.9 | 965 ± 39.3 |
Blood samples (6 mL each) were collected at the following time points for each Period: 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. The window for 0 to 12 hours was +/-2 minutes, for 24 hours was +/-5 minutes and for \>24 hours was equal to +/-15 to 60 minutes. Plasma concentrations of lenvatinib were quantified by LC-MS/MS methodology using a previously validated assay. The LLOQ for the assay was 0.25 ng/mL. AUC(0-t) was calculated by the linear-up log-down trapezoidal method. AUC(0-inf) was calculate as follows; (AUC(0-inf)) = (AUC(0-t)) + (Ct/Kel), where Ct is the last measurable drug concentration and Kel is the elimination rate constant. The apparent first-order Kel was estimated, when possible, from the slope of the regression line for the terminal ln-linear concentration-time values.
| ng·hr/mL | Treatment 1: Low Crystal Form | Treatment 2: Reference Crystal Form | Treatment 3: High Crystal Form |
|---|---|---|---|
| Area Under the Concentration-Time Curve From Zero Time (Predose) Extrapolated to Infinite Time (AUC(0-inf)) | 1030 ± 40.0 | 1020 ± 36.9 | 991 ± 39.0 |
Blood samples (6 mL each) were collected at the following time points for each Period: 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. The window for 0 to 12 hours was +/-2 minutes, for 24 hours was +/-5 minutes and for \>24 hours was equal to +/-15 to 60 minutes. Plasma concentrations of lenvatinib were quantified by LC-MS/MS methodology using a previously validated assay. The LLOQ for the assay was 0.25 ng/mL.
| ng·hr/mL | Treatment 1: Low Crystal Form | Treatment 2: Reference Crystal Form | Treatment 3: High Crystal Form |
|---|---|---|---|
| Area Under the Concentration-Time Curve From Zero Time (Predose) to 24 Hours (AUC(0-24)) | 791 ± 47.4 | 792 ± 39.2 | 740 ± 43.5 |
Blood samples (6 mL each) were collected at the following time points for each Period: 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. The window for 0 to 12 hours was +/-2 minutes, for 24 hours was +/-5 minutes and for \>24 hours was equal to +/-15 to 60 minutes. Plasma concentrations of lenvatinib were quantified by LC-MS/MS methodology using a previously validated assay. The LLOQ for the assay was 0.25 ng/mL.
| ng·hr/mL | Treatment 1: Low Crystal Form | Treatment 2: Reference Crystal Form | Treatment 3: High Crystal Form |
|---|---|---|---|
| Area Under the Concentration-Time Curve From Zero Time (Predose) to 72 Hours (AUC(0-72)) | 975 ± 40.5 | 971 ± 36.7 | 923 ± 39.4 |
Blood samples (6 mL each) were collected at the following time points for each Period: 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. The window for 0 to 12 hours was +/-2 minutes, for 24 hours was +/-5 minutes and for \>24 hours was equal to +/-15 to 60 minutes. Plasma concentrations of lenvatinib were quantified by LC-MS/MS methodology using a previously validated assay. The LLOQ for the assay was 0.25 ng/mL.
| ng/mL | Treatment 1: Low Crystal Form | Treatment 2: Reference Crystal Form | Treatment 3: High Crystal Form |
|---|---|---|---|
| Maximum Observed Concentration (Cmax) of Lenvatinib in Plasma | 96.0 ± 64.0 | 97.1 ± 49.2 | 88.0 ± 57.7 |
Blood samples (6 mL each) were collected at the following time points for each Period: 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. The window for 0 to 12 hours was +/-2 minutes, for 24 hours was +/-5 minutes and for \>24 hours was equal to +/-15 to 60 minutes. Plasma concentrations of lenvatinib were quantified by LC-MS/MS methodology using a previously validated assay. The LLOQ for the assay was 0.25 ng/mL.
| Hours | Treatment 1: Low Crystal Form | Treatment 2: Reference Crystal Form | Treatment 3: High Crystal Form |
|---|---|---|---|
| Time to Cmax (Tmax) for Lenvatinib | 3.000 (1.00 to 12.00) | 3.000 (1.00 to 12.02) | 3.000 (2.00 to 12.02) |
Blood samples (6 mL each) were collected at the following time points for each Period: 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. The window for 0 to 12 hours was +/-2 minutes, for 24 hours was +/-5 minutes and for \>24 hours was equal to +/-15 to 60 minutes. Plasma concentrations of lenvatinib were quantified by LC-MS/MS methodology using a previously validated assay. The LLOQ for the assay was 0.25 ng/mL.
| Hours | Treatment 1: Low Crystal Form | Treatment 2: Reference Crystal Form | Treatment 3: High Crystal Form |
|---|---|---|---|
| Terminal Elimination Phase Half-life (t1/2) | 24.1 ± 6.88 | 24.2 ± 6.23 | 23.5 ± 6.61 |
Safety assessments consisted of monitoring and recording all adverse events (AEs) (serious and non-serious); regular monitoring of hematology, blood chemistry and urine values; periodic measurement of vital signs and electrocardiograms, performance of physical examinations. A TEAE was defined as an AE that emerges during treatment, having been absent at pretreatment (Baseline), or reemerges during treatment, having been present at pretreatment but stopped before treatment, or worsens in severity during treatment relative to the pretreatment state, when the AE is continuous. TEAEs considered by the investigator to be possibly or probably related to study drug, or TEAEs with missing causality, were included.
| Percentage of participants | Treatment 1: Low Crystal Form | Treatment 2: Reference Crystal Form | Treatment 3: High Crystal Form |
|---|---|---|---|
| TEAEs | 23.7 | 23.7 | 20.3 |
| Treatment-related TEAEs | 18.6 | 15.2 | 16.9 |
| Severe TEAEs | 1.69 | 0 | 0 |
| Serious TEAEs | 1.69 | 0 | 0 |
Collected over From date of first dose up to 30 days after the last dose of study treatment, up to approximately 2 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment 1: Low Crystal Form | 0/59 (0%) | 1/59 (1.7%) | 14/59 (23.7%) |
| Treatment 2: Reference Crystal Form | 0/59 (0%) | 0/59 (0%) | 14/59 (23.7%) |
| Treatment 3: High Crystal Form | 0/59 (0%) | 0/59 (0%) | 12/59 (20.3%) |
| Event | Treatment 1: Low Crystal Form | Treatment 2: Reference Crystal Form | Treatment 3: High Crystal Form |
|---|---|---|---|
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/59 | 0/59 | 0/59 |
| Event | Treatment 1: Low Crystal Form | Treatment 2: Reference Crystal Form | Treatment 3: High Crystal Form |
|---|---|---|---|
| HeadacheNervous system disorders | 2/59 | 4/59 | 6/59 |
| Blood pressure increasedInvestigations | 2/59 | 2/59 | 1/59 |
| Increased appetiteMetabolism and nutrition disorders | 2/59 | 0/59 | 0/59 |
| Burning sensationNervous system disorders | 2/59 | 0/59 | 0/59 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/59 | 0/59 | 2/59 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 0/59 | 2/59 | 0/59 |
| PapuleSkin and subcutaneous tissue disorders | 2/59 | 0/59 | 0/59 |
| PruritusSkin and subcutaneous tissue disorders | 2/59 | 0/59 | 0/59 |
| Abdominal painGastrointestinal disorders | 0/59 | 0/59 | 1/59 |
| ConstipationGastrointestinal disorders | 0/59 | 1/59 | 0/59 |
Safety Analysis Set (SAS) included all participants who received at least one dose of study drug and had at least one postdose safety assessment.
| Age, Continuous(Years) | Sequence A | Sequence B | Sequence C | Sequence D | Sequence E | Sequence F | Total |
|---|---|---|---|---|---|---|---|
| Mean | 45.1 ± 9.55 | 45.1 ± 10.72 | 36.3 ± 13.41 | 40.4 ± 10.80 | 31.7 ± 10.36 | 37.8 ± 12.06 | 39.4 ± 11.77 |
| Sex: Female, Male(Participants) | Sequence A | Sequence B | Sequence C | Sequence D | Sequence E | Sequence F | Total |
|---|---|---|---|---|---|---|---|
| Female | 4 | 3 | 2 | 2 | 2 | 2 | 15 |
| Male | 6 | 7 | 8 | 8 | 8 | 8 | 45 |
The record gives a start of Jul 2013, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2019, 5 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenvatinib